Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05565443 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

MR-guided Focused Ultrasound Plus GCase

StatusRecruiting
PhaseNot applicable
SponsorInSightec
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Dec 31, 2025 to Dec 31, 2027 Completion date: Dec 31, 2026 to Dec 31, 2028 · Site contact updatedv4 Show 2 more changesShow less
    • Completion date: Dec 31, 2026 to Dec 31, 2028
    • Site contact updated
  2. Primary completion date: Dec 31, 2024 to Dec 31, 2025 Completion date: Dec 31, 2024 to Dec 31, 2026 · Eligibility criteria revisedv3 Show 2 more changesShow less
    • Completion date: Dec 31, 2024 to Dec 31, 2026
    • Eligibility criteria revised

    See this version in full on ClinicalTrials.gov ↗

  3. Trial status: Not Yet Recruiting to Recruiting Primary and study completion dates: Dec 31, 2023 to Dec 31, 2024 · Primary endpoint revised · Study sites: 0 to 1 · 2 morev2 Show 5 more changesShow less
    • Primary and study completion dates: Dec 31, 2023 to Dec 31, 2024
    • Primary endpoint revised
    • Study sites: 0 to 1
    • Start date changed from estimate of Oct 15, 2022 to Nov 30, 2022
    • Secondary endpoint revised

    See this version in full on ClinicalTrials.gov ↗

  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
InSightec
42 trials monitored
See 1 trial at risk
Parkinson's Disease
1,435 trials monitored
See 62 trials at risk
The goal of this study is to establish safety and feasibility of intracerebral delivery of GCase via MRgFUS. This technique may offer potential benefits given the exposure of the putamen to GCase in animal models has been shown to be efficacious in improving Parkinson's disease pathology and phenotype.
Trial Details
NCT Number NCT05565443
Lead Sponsor InSightec
Conditions Parkinsons Disease
Enrollment 14 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov